EPS for Soligenix, Inc. (SNGX) Expected At $-0.22

March 14, 2018 - By Dolores Ford

 EPS for Soligenix, Inc. (SNGX) Expected At $ 0.22

Analysts expect Soligenix, Inc. (NASDAQ:SNGX) to report $-0.22 EPS on March, 26.They anticipate $0.05 EPS change or 29.41 % from last quarter’s $-0.17 EPS. After having $-0.17 EPS previously, Soligenix, Inc.’s analysts see 29.41 % EPS growth. The stock decreased 0.50% or $0.01 during the last trading session, reaching $2.01. About 16,197 shares traded. Soligenix, Inc. (NASDAQ:SNGX) has declined 63.52% since March 14, 2017 and is downtrending. It has underperformed by 80.22% the S&P500.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company has market cap of $17.55 million. It operates through two divisions, BioTherapeutics and Vaccines/BioDefense. It currently has negative earnings. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis.

More notable recent Soligenix, Inc. (NASDAQ:SNGX) news were published by: Globenewswire.com which released: “Soligenix, Inc. (Nasdaq: SNGX) to Ring The Nasdaq Stock Market Closing Bell” on August 30, 2017, also Prnewswire.com with their article: “Soligenix to Present at the 12th Annual International Partnering Conference …” published on March 13, 2018, Prnewswire.com published: “Soligenix Announces Reverse-Split in Preparation for Proposed Up-Listing of …” on October 07, 2016. More interesting news about Soligenix, Inc. (NASDAQ:SNGX) were released by: Prnewswire.com and their article: “Soligenix Announces Recent Accomplishments And Third Quarter 2017 Financial …” published on November 06, 2017 as well as Prnewswire.com‘s news article titled: “Soligenix Announces US Patent Issuance for Use of Dusquetide in Oral Mucositis” with publication date: January 02, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: